Zhitong Finance App learned that VVVV.US (VVVV.US) submitted an initial public offering (IPO) application to the US Securities and Exchange Commission (SEC) on Friday. The company specializes in self-developed non-invasive repair treatments for early dental caries treatment. The IPO is expected to raise 200 million US dollars.
According to information, the company develops and sells Curodont, a peptide-based treatment for early dental caries that can be completed in five minutes or less in dental clinics without drilling or injections. Its American product Curodont Repair Fluoride Plus is sold as an over-the-counter drug according to FDA monographs, contributing the vast majority of revenue. The fluoride-free version of Curodon Repair is sold as a medical device in the UK and some European regions. The company sells only through Henry Schein in the US, and is supported by its own sales team. Its products have been sold to over 20,000 of the approximately 110,000 general dental clinics in the US.
The company, headquartered in Zug, Switzerland, was founded in 2020 and achieved revenue of 50 million US dollars in the 12 months ending June 30, 2026. The company plans to list on the New York Stock Exchange under the ticker symbol VVVV. VvarDis Holding secretly submitted an application on July 2, 2026. Goldman Sachs, J.P. Morgan Chase, William Blair, UBS Investment Bank, Deutsche Bank, and Apollo Global Securities acted as joint bookkeepers for the transaction. Terms relating to release pricing have not yet been disclosed.